TransMedics Gr Q2 EPS $(0.03) Beats $(0.13) Estimate, Sales $52.47M Beat $42.42M Estimate
Portfolio Pulse from bharat@benzinga.com
TransMedics Gr (NASDAQ:TMDX) reported Q2 EPS of $(0.03), beating the analyst consensus estimate of $(0.13) by 76.92%. This is a 92.68% increase over losses from the same period last year. The company also reported quarterly sales of $52.47M, beating the analyst consensus estimate of $42.42M by 23.68%. This is a 155.66% increase over sales from the same period last year.
August 04, 2023 | 2:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TransMedics Gr's Q2 earnings and sales significantly beat estimates, showing strong growth compared to the same period last year.
TransMedics Gr's Q2 earnings and sales beat estimates, which is a positive signal for investors. The significant growth compared to the same period last year indicates strong performance and potential future growth, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100